41 results about "Remission rate" patented technology

The invention relates to a traditional Chinese medicine for treating prostatic cancer, characterized by comprising the following medicinal raw materials in proportion: 10-30 parts of astragalus root, 10-15 parts of angelica, 8-12 parts of euryale seed, 6-8 parts of antler, 10-15 parts of glossy privet fruit, 10-20 parts of gardenia fruit, 10-30 parts of honeysuckle, 10-15 parts of weeping forsythia, 6-10 parts of java brucea fruit, 8-12 parts of red peony root, 6-10 parts of hemp root, 10-15 parts of lotus root node, 10-14 parts of madder root, 8-10 parts of longhairy antenoron herb, 8-12 parts of climbing fern spore, 10-18 parts of mulberry bark and 6-10 parts of licorice. After the medicinal raw materials are selected, mixed and soaked, water is added for decocting, one dose of decoction is 200ml, 100ml of decoction is taken orally twice per day respectively in the morning and at night, and one course of treatment lasts for 10 days. The invention has the beneficial effects that the overall treatment concept for strengthening the body resistance and resisting cancer has the following therapeutic principles of: invigorating qi and nourishing the blood, strengthening the kidney and expelling toxin, dissipating blood stasis and alleviating pain, promoting blood circulation and arresting bleeding, and regulating internal secretion; diagnosis and treatment are based on an overall analysis of the illness and the condition of a patient clinically according to different syndromes; and the recurrence, spread and metastasis of cancer are effectively controlled. The medicine has quick curative effect, high remission rate and no toxic side effect.

The invention discloses a pharmaceutical composition for treating leukaemia. The composition is made from the following raw materials: 10-50 parts of anhydrogalactitol, 30-50 parts of angelica, 30-50 parts of astragalus root, 15-50 parts of ginseng, 15-50 parts of red sage root, 15-50 parts of pilose asiabell root and 10-30 parts of figwirt root. The pharmaceutical composition has obvious effects on treating the leukaemia, certain curative effect on lung cancer, multiple myeloma, nasopharyngeal carcinoma and the like, especially good short-term curative effect on chronic granulocytic leukemia with a remission rate up to 86%, higher effective rate on various lung cancers and less toxic side effect.

The invention discloses a traditional Chinese medicinal preparation for treating primary thrombocytopenia, which is prepared from the following raw material medicaments in part by weight: 10 to 50 parts of cassia bark, 30 to 50 parts of large-headed atractylodes rhizome, 30 to 50 parts of astragalus, 15 to 50 parts of szechwon tangshen root, 15 to 50 parts of root of red-rooted salvia, 15 to 50 parts of szechuan lovage rhizome and 10 to 30 parts of glossy ganoderma. The traditional Chinese medicinal preparation has the obvious curative effect on leukemia, has a certain curative effect on lung cancer, myeloma multiplex, nasopharyngeal darcinoma and the like and particularly has the good short-term curative effect on primary thrombocytopenic purpura, and has 86 percent of remission rate and low toxic and side effect.

The invention relates to a combined medicine for curing treatment-resistant depression (TRD), which is characterized in that the combined medicine comprises paroxetine and sodium valproate. The invention also provides applications of the combined medicine. The invention has the advantages that the research on the TRD synergia strategy is provided for the first time in China, the combined medicine of paroxetine and sodium valproate, and the applications of the combined medicine in the preparation of medicine for curing the TRD are provided for the first time, the paroxetine combined with the sodium valproate for curing the TRD has higher remission rate, and the tolerance is high, so that the combined medicine can be taken as the new intensive treatment scheme for curing the TRD.

The invention relates to the technical field of medicines, in particular to a stem cell preparation and an application of the stem cell preparation in preparing a drug for treating chronic nephritis. The provided stem cell preparation is prepared through resuspension of umbilical cord mesenchymal stem cells by the aid of normal saline, the content of urine protein of a patient and the number of urine erythrocyte are reduced by inhibiting expression of T cell surface antigen CD8 and secretion of INF-gamma and up-regulating secretion of IL-4 of T lymphocyte of peripheral blood, so that the effect for treating chronic nephritis is realized, the effective rate of treatment can reach 88%, and the remission rate can reach 54%.

The invention discloses a lumbar facet joint fusion device and its implantation device. The lumbar facet joint fusion device comprises an oblate spheroid, and the two ends of the oblate spheroid are respectively provided with upper and lower cylinders with overlapping central axes and the same diameter; the oblate spheroid The diameter of the upper and lower cylinders is 6mm and the height is 4mm; the diameter of the upper and lower cylinders is 4mm, the height of the upper cylinder is 2mm, and the height of the lower cylinder is 1mm; the oblate spheroid and the upper and lower cylinders are made of cortical bone material of adult femur. Implantation devices include positioners, working channels, straight drills, ball drills, and implanters. The present invention can improve the fusion rate of lumbar facet joints in the medium and long term and the relief rate of postoperative symptoms, eliminate the loosening and breakage of screws, and reduce the side effects of screws such as dura mater tearing, puncture into spinal canal, and nerve damage. The implanting device is simple, easy to operate, and has good use effect.

The invention relates to a traditional Chinese medicine composition for treating recurrence of meningiomas after the surgery. The traditional Chinese medicine is characterized by comprising the following raw materials: 6-9g of frankincense, 6-8g of myrrh, 3-6g of stiff silkworm, 6-10g of salvia chinensis, 6-10g of curcuma zedoary, 3-6g of edible tulip, 6-8g of ligusticum wallichii, 6-8g of red-rooted salvia root, 4-6g of radix angelicae, 6-8g of red peony root, 4-6g of caulis spatholobi, 3-6g of sculellaria barbata, 3-6g of self heal, 4-6g of mangnolia officinalis, 4-6g of coix seed, 6-8g of codonopsis pilosula, 4-6g of angelica, 4-6g of tuckahoe, 4-6g of rhizoma alismatis and 4-6g of liquorice. The traditional Chinese medicine composition has the beneficial effects of promoting blood circulation for removing blood stasis, supporting the healthy energy, resolving hard lump and inducing diuresis to alleviate edema. The traditional Chinese medicine composition has the characteristics of good treatment effect, high remission rate, low cost and low toxic side effect. The recurrence of meningiomas is dialectically treated according to different symptom patterns in clinical science.

The invention relates to the field of traditional Chinese medicine, in particular to a traditional Chinese medicine decoction for curing limb pain caused by diabetic neuropathy, which is composed of corn stigma, Coptis chinensis, root of rehmannia, Radix Ophiopogonis, radix scrophulariae, Angelica sinensis, the root of red-rooted salvia, root of common peony, Ligusticum wallichii, leonurus, peach kernel paste, Astragalus mongholicus, rhizoma atractylodis, Asarum sieboldi Mig, Poria cocos, rhizoma alismatis, red flower, Caulis Spatholobi, corydalis tuber, Schisandra chinensis, liquorice and spina date seed. The traditional Chinese medicine decoction for curing limb pain caused by diabetic neuropathy is low in cost, high in curing rate and free of toxic and side effects and has the function of nourishing yin and engendering liquid, promoting blood circulation and removing stasis and dredging collateral and removing pain. The total effective rate is 95%, the remission rate is 80%, the improvement rate is 15% and the failure rate is 5%.

The present invention discloses a drug for treating acute leukemia and refractory acute leukemia, the components of the pharmaceutical raw materials of the drug composition are: 5 to 20 parts by weight of thunberg fritillary bulb, 5 to 20 parts by weight of fourstamen stephania root and 2 to 12 parts by weight of Szechuan lovage rhizome. The present invention provides an application of the thunberg fritillary bulb composition in the adjuvant chemotherapy to improve the clinical efficacy of the refractory acute leukemia; the present invention carries out a large amount of experiments, which takes the clinical remission rate as the clinical efficacy evaluation index and takes the heart, liver, renal function etc. as the safety indexes and the detection indexes, the results prove that the thunberg fritillary bulb composition has better clinical efficacy in the adjuvant chemotherapy to improve the clinical efficacy of the refractory acute leukemia and also has the better clinical medication safety.